Log in

NASDAQ:LENSPresbia Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $0.03
50-Day Range
MA: $0.15
52-Week Range
Now: $0.03
Average Volume122,366 shs
Market Capitalization$516,900.00
P/E RatioN/A
Dividend YieldN/A
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.
Read More
Presbia logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.85 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:LENS



Sales & Book Value

Annual Sales$20,000.00
Book Value$0.09 per share


Net Income$-8,410,000.00
Net Margins-36,604.35%


Market Cap$516,900.00
Next Earnings DateN/A
OptionableNot Optionable

Receive LENS News and Ratings via Email

Sign-up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter.

Presbia (NASDAQ:LENS) Frequently Asked Questions

How were Presbia's earnings last quarter?

Presbia PLC (NASDAQ:LENS) released its quarterly earnings results on Friday, August, 12th. The medical instruments supplier reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.07. The medical instruments supplier earned $0.01 million during the quarter, compared to analyst estimates of $0.04 million. Presbia had a negative net margin of 36,604.35% and a negative return on equity of 414.02%. View Presbia's earnings history.

Has Presbia been receiving favorable news coverage?

Press coverage about LENS stock has been trending negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Presbia earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Presbia.

Who are some of Presbia's key competitors?

What other stocks do shareholders of Presbia own?

Who are Presbia's key executives?

Presbia's management team includes the following people:
  • Mr. Vladimir Feingold, Consultant (Age 70)
  • Mr. Mark T. Yung, CEO & Chairman (Age 45)
  • Mr. Valeriano Lima, Corp. Controller, Head of Financial Planning and Analysis & Company Sec. (Age 37)
  • Ms. Casey Jean Lind, Chief Operating Officer (Age 57)
  • Mr. Richard T. Fogarty, Consultant (Age 68)

When did Presbia IPO?

(LENS) raised $50 million in an IPO on Thursday, January 29th 2015. The company issued 4,200,000 shares at a price of $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO.

What is Presbia's stock symbol?

Presbia trades on the NASDAQ under the ticker symbol "LENS."

What is Presbia's stock price today?

One share of LENS stock can currently be purchased for approximately $0.03.

How big of a company is Presbia?

Presbia has a market capitalization of $516,900.00 and generates $20,000.00 in revenue each year. Presbia employs 24 workers across the globe.

What is Presbia's official website?

The official website for Presbia is www.presbia.com.

How can I contact Presbia?

Presbia's mailing address is SANDYFORD OFFICE CENTRE SUITE 7 17 CORRIG ROAD, DUBLIN 18 L2, . The medical instruments supplier can be reached via phone at 353-551-1487.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.